|
Jul 24
|
REGENXBIO Inc. (RGNX): A Bull Case Theory
|
|
Jul 18
|
REGENXBIO Inc. (NASDAQ:RGNX) is largely controlled by institutional shareholders who own 67% of the company
|
|
Jul 10
|
REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy
|
|
Jun 5
|
REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
|
|
Jun 2
|
REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202
|
|
Apr 22
|
Trump’s FDA Sends a Bullish Signal to Biotech
|
|
Mar 14
|
Q4 2024 Regenxbio Inc Earnings Call
|
|
Mar 14
|
Regenxbio Inc (RGNX) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Resilience
|
|
Mar 13
|
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
|
|
Mar 13
|
Regenxbio: Q4 Earnings Snapshot
|
|
Mar 13
|
REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates
|
|
Mar 10
|
REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
|
|
Feb 20
|
Castle Biosciences, Inc. (CSTL) Reports Next Week: Wall Street Expects Earnings Growth
|